Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: Results of the TREE study (vol 26, pg 3523, 2008)

被引：1
|
作者：
Hochster
机构：
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2008年 / 26卷 / 28期
关键词：
D O I：
10.1200/JCO.2008.19.8630
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：4697 / 4697
页数：1
相关论文
共 50 条
  • [1] Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: Results of the TREE study
    Hochster, Howard S.
    Hart, Lowell L.
    Ramanathan, Ramesh K.
    Childs, Barrett H.
    Hainsworth, John D.
    Cohn, Allen L.
    Wong, Lucas
    Fehrenbacher, Louis
    Abubakr, Yousif
    Saif, M. Wasif
    Schwartzberg, Lee
    Hedrick, Eric
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (21) : 3523 - 3529
  • [2] Safety and efficacy of oxaliplatin/fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer (mCRC): Final analysis of the TREE-Study.
    Hochster, H. S.
    Hart, L. L.
    Ramanathan, R. K.
    Hainsworth, J. D.
    Hedrick, E. E.
    Childs, B. H.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 148S - 148S
  • [3] Safety, tolerability and efficacy of the addition of bevacizumab to oxaliplatin/fluoropyrimidine regimens as first-line treatment of metastatic colorectal cancer (mCRC): Results of TREE 2 cohort of the TREE study
    Hochster, H.
    Hart, L.
    Ramanathan, R. K.
    Hainsworth, J.
    Griffing, S.
    Mass, R.
    Nagarwala, Y.
    Jirau-Lucca, G.
    Shpilsky, A.
    Childs, B. H.
    [J]. EJC SUPPLEMENTS, 2005, 3 (02): : 173 - 173
  • [4] Safety of bevacizumab with fluoropyrimidine-based regimens for first-line teatment of metastatic colorectal cancer
    Tyagi, Preeta
    Chu, Edward
    [J]. CLINICAL COLORECTAL CANCER, 2006, 6 (03) : 189 - 191
  • [5] Safety and efficacy of bevacizumab (Bev) when added to oxaliplatin/fluoropyrimidine (O/F) regimens as first-line treatment of metastatic colorectal cancer (mCRC): TREE 1 & 2 Studies.
    Hochster, HS
    Welles, L
    Hart, L
    Ramanathan, RK
    Hainsworth, J
    Jirau-Lucca, G
    Shpilsky, A
    Griffing, S
    Mass, R
    Emanuel, D
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 249S - 249S
  • [6] Bevacizumab in combination with fluoropyrimidine-irinotecan- or fluoropyrimidine-oxaliplatin-based chemotherapy for first-line and maintenance treatment of metastatic colorectal cancer
    Grapsa, Dimitra
    Syrigos, Konstantinos
    Saif, Muhammad Wasif
    [J]. EXPERT REVIEW OF ANTICANCER THERAPY, 2015, 15 (11) : 1267 - 1281
  • [7] Bevacizumab in Combination With Oxaliplatin-Based Chemotherapy As First-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III Study (vol 26, pg 2013, 2008)
    Saltz
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (04) : 653 - 653
  • [8] Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: A randomized phase III study (vol 26, pg 2013, 2008)
    Saltz
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (18) : 3110 - 3110
  • [9] Efficacy and safety of bevacizumab with standard first-line fluoropyrimidine-based chemotherapy in patients with metastatic colorectal cancer: First beat
    Rivera, F.
    Cunningham, D.
    Berry, S.
    Kretzschmar, A.
    Michael, M.
    Dibartolomeo, M.
    Mazier, M.
    Andre, N.
    Van Cutsem, E.
    [J]. ANNALS OF ONCOLOGY, 2008, 19 : 17 - 17
  • [10] Efficacy and Safety of Oxaliplatin-based Regimens as First-line Chemotherapy in Elderly Patients With Metastatic Colorectal Cancer
    Yamamoto, Seiji
    Fujii, Hironori
    Murayama, Kotaro
    Iihara, Hirotoshi
    Watanabe, Daichi
    Yamada, Yunami
    Kobayashi, Ryo
    Kiyama, Shigeru
    Makiyama, Akitaka
    Urano, Kimihiko
    Matsuhashi, Nobuhisa
    Matsuura, Katsuhiko
    Suzuki, Akio
    [J]. ANTICANCER RESEARCH, 2023, 43 (11) : 5099 - 5105
12345